Stockhouse.com uses cookies on this site. By continuing to use our service, you agree to our use of cookies. Cookies are used to offer you a better browsing experience and to analyze our traffic. We also use them to share usage information with our partners. See full details.
I Agree
×
Join today and have your say! It’s FREE!

Become a member today, It's free!

We will not release or resell your information to third parties without your permission.
Please Try Again
{{ error }}
By providing my email, I consent to receiving investment related electronic messages from Stockhouse.

or

Privacy Policy | Disclaimer

Sign In

Please Try Again
{{ error }}
Password Hint : {{passwordHint}}
Forgot Password?

or

Privacy Policy | Disclaimer
Please Try Again {{ error }}

Send my password

Return to Login
SUCCESS
An email was sent with password retrieval instructions. Please go to the link in the email message to retrieve your password.

Become a member today, It's free!

We will not release or resell your information to third parties without your permission.
News Focus
Saturn Oil & Gas Inc. Announces its First Development of Cardium Wells at Brazeau and Continued Successful Development (click to learn more)
Quote  |  Bullboard  |  News  |  Opinion  |  Profile  |  Peers  |  Filings  |  Financials  |  Options  |  Price History  |  Ratios  |  Ownership  |  Insiders  |  Valuation

Breaking & Recent News Avalo Therapeutics Inc AVTX

Healthcare Biotechnology
Avalo Therapeutics, Inc. is a clinical-stage biotechnology company focused on the treatment of immune dysregulation. The Company's lead asset is AVTX-009, an anti-IL-1ß mAb, targeting inflammatory diseases. Its pipeline also includes quisovalimab (anti-LIGHT mAb) and AVTX-008 (BTLA agonist fusion protein). AVTX-009 is a humanized monoclonal antibody (IgG4) that binds to interleukin-1ß (IL-1ß... see more

Recent & Breaking News (NDAQ:AVTX)

Cerecor Reports Fourth Quarter and Full Year 2018 Results

Accesswire March 18, 2019

Cerecor Announces Closing of $10.0 Million Bought Deal of Common Stock

Accesswire March 11, 2019

Cerecor Increases Previously Announced Bought Deal of Common Stock to $10 Million

Accesswire March 6, 2019

Cerecor Announces $8 Million Bought Deal Offering

Accesswire March 5, 2019

64 Stocks Moving In Friday's Mid-Day Session

Benzinga.com  March 1, 2019

The Daily Biotech Pulse: Bristol-Myers Squibb-Celgene Deal Faces Setback, Syneos Hit By SEC Probe, FDA Cheer For T2 Biosystems

Benzinga.com  February 28, 2019

72 Biggest Movers From Yesterday

Benzinga.com  February 26, 2019

Cerecor Receives Fast Track Designation from FDA for CERC-801 for the Treatment of PGM1 Deficiency

GlobeNewswire February 19, 2019

52 Stocks Moving In Friday's Mid-Day Session

Benzinga.com  February 15, 2019

31 Stocks Moving In Friday's Pre-Market Session

Benzinga.com  February 15, 2019

Cerecor Announces CERC-301 Granted U.S. Patent

GlobeNewswire February 15, 2019

Cerecor Announces U.S. Headquarters Move Into Pharmaceutical Corridor of Rockville, Maryland

GlobeNewswire January 28, 2019

FDA Accepts IND Application for Cerecor’s Investigational Drug CERC-801 for the treatment of PGM1 Deficiency

GlobeNewswire January 22, 2019

58 Biggest Movers From Yesterday

Benzinga.com  January 17, 2019

FDA Grants Cerecor’s Three Substrate Replacement Therapies Orphan Drug Designation

GlobeNewswire January 16, 2019

Antares Pharma Announces the Appointment of Peter S. Greenleaf to Company’s Board of Directors

GlobeNewswire December 13, 2018

Analysis: Positioning to Benefit within KemPharm, Bellerophon Therapeutics, Exela Technologies, Intec Pharma, Cerecor, and Chiasma — Research Highlights Growth, Revenue, and Consolidated Results

GlobeNewswire November 21, 2018

Cerecor Reports Third Quarter 2018 Results

GlobeNewswire November 13, 2018

Cerecor Announces Submission of Three Orphan Drug Designation Requests for Substrate Replacement Therapies to treat Congenital Disorders of Glycosylation

GlobeNewswire October 31, 2018

Cerecor Receives Rare Pediatric Disease Designation for CERC-801 for Patients with Inborn Error of Metabolism

GlobeNewswire October 30, 2018